Guardant Health has partnered with Adicon, an independent clinical laboratory company based in China, to offer Guardant's comprehensive genomic profiling (CGP) cancer tests to biopharmaceutical companies conducting clinical trials in China.
As part of the relationship, Guardant Health will license to Adicon its liquid biopsy technology, including the Guardant360 and GuardantOmni tests, and the Guardant360 TissueNext tissue-based biopsy for patients with any solid cancerous tumor. These cancer tests are designed to help researchers identify patients whose cancer has the right molecular profile for their clinical programs, streamlining patient screening and clinical trial enrollment, and also providing insights into patient response, tumor evolution, and resistance. In addition, Guardant Reveal, a blood-only test developed to detect residual disease and to monitor for cancer recurrence, will be offered to biopharmaceutical companies for early-stage cancer research and development.
"Our partnership with Adicon marks another important milestone for Guardant Health, and we are excited to bring our comprehensive genomic profiling tests and services to researchers in China," said Helmy Eltoukhy, Guardant Health co-CEO. "With Adicon's extensive expertise in clinical laboratory services, we believe they are the ideal partner to help biopharmaceutical companies bring the next generation of cancer therapies to patients in the region."
The partnership transforms Adicon's ability to serve biopharmaceutical customers and beyond, according to Ling Yang, Adicon's chairwoman.
"Increasing incidence rates have made cancer a high priority in China and have led to a rising number of clinical trials in the region," said Lawrence Wang, CFO at Adicon. "With our CAP accredited laboratory in Shanghai, we are delighted to partner with Guardant Health to make its cancer tests available for biopharmaceutical partners in China."
Other recent Guardant Health news
The partnership with Adicon also follows Guardant's announcement June 13 that the company has purchased the remaining shares of Guardant Health AMEA, which had been held by SoftBank and its affiliates, giving the company full control over its operations throughout the Asia, Middle East, and Africa. The company had previously established the Guardant Health AMEA joint venture in May 2018 in an effort to expand commercialization of its liquid biopsy cancer tests across the region. Guardant paid about $177.8 million to buy out SoftBank and its affiliates.
“By acquiring the remaining shares of Guardant Health AMEA, we can focus on creating a unified and centralized global organization that delivers on our promise to help conquer cancer and improve patient outcomes,” Eltoukhy said. “We believe our blood-based tests can play a significant role in helping address the growing incidence of cancer in the region, and we look forward to continuing to support patients facing cancer diagnoses as we expand our operations in these markets.”